Humacyte is trading at $0.49, up 9.84%, in pre-market on October 9, 2026; no fresh company-specific announcement explaining the move was identified. - The latest company press release found was the September 9 Symvess shelf-life extension. - U.S. futures and major indices were higher, providing a broad risk-on backdrop, but available evidence does not establish that this caused the gain. - The rebound follows several declining closes, and its reason remains uncertain.